Guardant Health (NASDAQ:GH) CEO Sells $17,638,207.88 in Stock

Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz sold 116,972 shares of the business’s stock in a transaction on Friday, June 26th. The shares were sold at an average price of $150.79, for a total transaction of $17,638,207.88. Following the sale, the chief executive officer directly owned 1,881,336 shares of the company’s stock, valued at $283,686,655.44. This represents a 5.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amirali Talasaz also recently made the following trade(s):

• On Monday, June 29th, Amirali Talasaz sold 143,028 shares of Guardant Health stock. The stock was sold at an average price of $151.54, for a total transaction of $21,674,463.12.
• On Wednesday, May 20th, Amirali Talasaz sold 210,000 shares of Guardant Health stock. The stock was sold at an average price of $109.89, for a total transaction of $23,076,900.00.
• On Tuesday, May 12th, Amirali Talasaz sold 50,000 shares of Guardant Health stock. The shares were sold at an average price of $100.32, for a total transaction of $5,016,000.00.

Guardant Health Stock Performance

Guardant Health stock traded down $3.71 during trading hours on Tuesday, hitting $150.03. The company had a trading volume of 3,327,903 shares, compared to its average volume of 2,298,095. The firm has a market cap of $19.89 billion, a P/E ratio of -44.26 and a beta of 1.61. Guardant Health, Inc. has a 1 year low of $40.35 and a 1 year high of $153.95. The company has a 50-day moving average price of $113.99 and a two-hundred day moving average price of $104.38.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GH. Piper Sandler set a $127.00 price objective on Guardant Health in a research note on Thursday, May 21st. BTIG Research set a $160.00 target price on Guardant Health and gave the company a “buy” rating in a research report on Wednesday, May 27th. Wolfe Research started coverage on Guardant Health in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $150.00 target price for the company. Mizuho increased their price target on Guardant Health from $135.00 to $175.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Finally, JPMorgan Chase & Co. raised their price target on Guardant Health from $130.00 to $135.00 and gave the company an “overweight” rating in a research note on Friday, May 8th. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $144.82.

Hedge Funds Weigh In On Guardant Health

Several institutional investors have recently bought and sold shares of GH. Vanguard Group Inc. raised its stake in Guardant Health by 2.1% in the fourth quarter. Vanguard Group Inc. now owns 12,160,768 shares of the company’s stock worth $1,242,101,000 after buying an additional 251,939 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in Guardant Health by 33.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,636,078 shares of the company’s stock valued at $575,670,000 after acquiring an additional 1,414,441 shares in the last quarter. Franklin Resources Inc. boosted its position in Guardant Health by 14.9% during the 4th quarter. Franklin Resources Inc. now owns 3,361,547 shares of the company’s stock valued at $343,348,000 after acquiring an additional 435,232 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Guardant Health by 9.4% in the 4th quarter. Geode Capital Management LLC now owns 3,213,657 shares of the company’s stock valued at $328,297,000 after acquiring an additional 277,001 shares during the period. Finally, Fuller & Thaler Asset Management Inc. increased its holdings in shares of Guardant Health by 3.0% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 2,441,730 shares of the company’s stock valued at $249,398,000 after acquiring an additional 72,162 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.